Table 5 Studies evaluating the significance of anti-CCP titer in patients with undifferentiated arthritis (UA)
Author [ref] | Patients, n | UA | UA duration | FU | Anti-CCP | CCP+ baseline | UA outcome | Anti-CCP titer significance |
|---|---|---|---|---|---|---|---|---|
Kudo-Tanaka [27] | 146 | ≥ 2 Sj | ≤ 2 yr | 1 yr | ≥ 5 U/ml no serial assay | 17% | 12% RA 37% non-RA 41% UA | 164 ± 136 RA vs 55 ± 72 non-RA/UA P = 0.017 |
Guzian [18] | 253 (83% RA baseline) | ≥ 3 Sj | ≤ 1 yr | 30 mo. | ≥ 20 U/ml serial assay (0.30 mo.) | 38% | 17% RA | No correlation low-high CCP/DAS28, HAQ, erosions |
Ursum [31] | 545 | ≥ 2 Sj | ≤ 3 yr | 2 yr | ≥ 5 U/ml serial assay (0.1 yr) | 56% | 63% RA baseline or at 1 yr | No correlation CCP change/DAS28, HAQ, SHS |
Emad [28] | 69 | ≥ 1 Sj | ≤ 1 yr | 1 yr | ≥ 2.9 U/ml no serial assay | 59% | 26% RA 6% PsA 41% UA 26% remission | Correlation CCP titer/Sj, Tj, ESR, erosions |
Bos [30] | 147 | arthralgia | 12 (7-36) mo. median | 28 (19-39) mo. median | ≥ 5 U/ml no serial assay | 34% | 7% RA 13% ≥ 4Sj 80% no-arthritis | Median 141 arthritis vs 31 U/ml non-arthritis HR = 1.7 |
Mjaavatten [29] | 376 (19% RA baseline) | ≥ 1 Sj | ≤ 16 wk | 1 yr | ≥ 25 U/ml no serial assay | 16% | 46% persistent 54% self-limiting | 25-100 OR 4.4 101-250 OR = 9.4 > 250 OR = 14 for persistence |
Burr [21] | 640 (49% RA baseline) | ≥ 2 Sj | ≥ 4 wk | 5 yr | ≥ 5 U/ml serial assay (0.5 yr) | 30% | 72% RA 28% non-RA | Median 1.6 U/ml RA vs 0.8 U/ml non-RA |
Present study | 192 | ≥ 1 Sj | ≤ 12 wk | 2 yr | serial assay (0.6,12,18,24 mo.) | 42% | 37% RA 30% UA 17% self-limiting 16% non-RA RD | Correlation titer/time to RA onset and RA development |